Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Santhera to discontinue sale of Catena® in Canada
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
The role of T cell apoptosis in nervous system autoimmunity.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Optimizing IFN Beta - 1B Dose (Optims)
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.

Pages